Famous Patents
The ice cream cone was invented at the St. Louis Worlds Fair by Ernest Hamwi in 1904. His waffle booth was next to an ice cream vendor who ran short of dishes. Hamwi rolled a waffle to hold ice cream and the cone was born.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8187614 | Method of using lectins for prevention and treatment of oral and alimentary tract disorders Infectious diseases caused by pathogenic microorganisms resident in the alimentary tract of humans and animals can be prevented and treated by administering to the alimentary tract of the human or animal an effective amount of a composition containing at least one l... | 05/29/2012 |
| 8182823 | Compositions and methods for the therapy and diagnosis of breast cancer Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antige... | 05/22/2012 |
| 8173140 | Compositions and methods for activating innate and allergic immunity Methods for making and using therapeutic formulations of Proteosome-based immunoactive compositions are provided. The immunogenic compositions, which include Proteosomes and liposaccharides, may be used to elicit or enhance a nonspecific innate immune response to, f... | 05/08/2012 |
| 8173141 | Immunogenic complexes and methods relating thereto The present invention relates generally to an immunogenic complex comprising a charged organic carrier and a charged antigen and, more particularly, a negatively charged organic carrier and a positively charged antigen. The complexes of the present invention are use... | 05/08/2012 |
| 8153141 | Immunostimulatory G, U-containing oligoribonucleotides Compositions and methods relating to immunostimulatory RNA oligomers are provided. The immunostimulatory RNA molecules are believed to represent natural ligands of one or more Toll-like receptors, including Toll-like receptor 7 (TLR7) and Toll-like rec... | 04/10/2012 |
| 8142798 | Augmentation of titer for vaccination in animals The disclosure relates to a composition added to animal feed used in combination with a vaccine to enhance the effectiveness of the vaccine. Amongst other effects, the composition raises the titer of antibodies to the vaccine. ... | 03/27/2012 |
| 8137682 | Isolated complexes of covalently cross-linked endotoxin and modified MD-2 Applicants have produced and isolated chemically cross-linked complexes of endotoxin and modified MD-2, and have developed methods of using these complexes. ... | 03/20/2012 |
| 8128944 | RNA sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles Immunostimulatory polymers that contain certain sequence-dependent immunostimulatory RNA motifs and methods for the use of such immunostimulatory polymers and compositions containing such polymers are provided according to the invention. The sequence-dependent immun... | 03/06/2012 |
| 8124111 | Immunomodulation by altering sphingosine 1-phosphate lyase (SPL) activity Compositions and methods for modulating immune function are provided based on the unexpected discovery that inhibition of sphingosine-1-phosphate lyase (SPL) activity confers useful immunosuppressive effects, for example to modulate immune function in treatment or p... | 02/28/2012 |
| 8114418 | Chimeric immunomodulatory compounds and methods of using the same—IV The invention provides immunomodulatory compounds and methods for immunomodulation of individuals using the immunomodulatory compounds. ... | 02/14/2012 |
| 8114419 | Nucleic acid compositions for stimulating immune responses The invention provides an immunostimulatory nucleic acid comprising CpG motifs, and methods of use thereof in stimulating immunity. ... | 02/14/2012 |
| 8110203 | Adjuvant comprising non-toxic cross-linked muramyl dipeptide (MDP) microparticles derived from Propionibacterium acnes Methods and compositions for treatment, diagnosis, and prevention of a virus comprise administering to a patient antibodies which react with regions of viral proteins and result in neutralization of infectivity and inactivation of functionally essential events in th... | 02/07/2012 |
| 8110551 | Cytolethal distending toxin and use thereof This invention relates to immunotoxins and their use. Specifically, the invention relates to compositions comprising Cdt toxins or their inhibitors and their use in methods for treating infectious and proliferative diseases. ... | 02/07/2012 |
| 8092813 | Polychlorinated biphenyls and squalene-containing adjuvants When using squalene in a vaccine adjuvant, there is a possibility of contamination with polychlorinated biphenyls (PCBs). Environmental exposure to PCBs may adversely affect children's immune responses to routine vaccinations. Thus the invention uses squalene with l... | 01/10/2012 |
| 8088395 | Phytol derived immunoadjuvants and their use in vaccine formulations This invention relates to a novel immunoadjuvant, an adjuvant component, and vaccines containing the adjuvant component. The adjuvant includes phytol or a phytol derivative. The adjuvant component, when combined with a soluble or particulate antigen, provides a vacc... | 01/03/2012 |
| 8088397 | Human lymphocyte vaccine adjuvant The present invention relates to an adjuvant derived from human lymphocytes. The adjuvant can be used in combination with traditional vaccines or cancer immunotherapy, to enhance the response of the patient's immune system to the vaccine or other immunotherapeutic a... | 01/03/2012 |
| 8088396 | Isolated complexes of endotoxin and modified MD-2 Applicants have produced and isolated water soluble complexes of endotoxin and modified MD-2. ... | 01/03/2012 |
| 8063022 | Methods for preventing formation of inhibitory antibodies in the setting of gene therapy The invention provides a method of preventing the formation of inhibitory antibodies in a mammal undergoing gene therapy. The method comprises administering to the mammal an immunosuppressive agent in conjunction with the gene therapy. ... | 11/22/2011 |
| 8057810 | Peptide substance revealing an immunogeroprotective effect, pharmaceutical composition on its base and the method of its application Disclosed is a pharmaceutical composition for the prevention and correction of age-related disorders of cellular and humoral immunity and having an immunogeroprotective effect. The pharmaceutical composition includes a peptide glutamyl-aspartyl-proline with general ... | 11/15/2011 |
| 8052981 | Mono- and disaccharide derivatives The present invention includes a formulation comprising a physiological salt solution, or an oil-in-water emulsion, or a water immiscible solid phase, and an adjuvant comprising one or more disaccharide derivatives derived from cellobiose, gentiobiose, lactose, lact... | 11/08/2011 |
| 8030287 | DNA vaccine against North American spring viremia of carp virus In this application is described a novel DNA vaccine for Spring viremia of carp virus. The candidate vaccine a SVCV glycoprotein (G) gene from the North Carolina isolate. The DNA vaccine provides protection in vaccinated fish against challenge with the SVCV. ... | 10/04/2011 |
| 7998492 | Methods and products related to treatment and prevention of hepatitis C virus infection The invention provides methods for identifying and treating subjects having hepatitis C infections. In some instances, the subjects are those that are non-responsive to non-CpG therapy. Preferably, the subjects are treated with C class CpG immunostimulatory nucleic ... | 08/16/2011 |
| 7993659 | TLR9 agonist and CD40 agonist immunostimulatory combinations The present invention provides immunostimulatory combinations. Generally, the immunostimulatory combinations include a TLR agonist and a TNF/R agonist. Certain immunostimulatory combinations also may include an antigen. ... | 08/09/2011 |
| 7993660 | Method of increasing immunological effect A method of increasing immunological effect in a patient by administering an effective amount of a primary cell derived biologic to the patient, inducing immune production, blocking immune destruction, and increasing immunological effect in the patient. Methods of t... | 08/09/2011 |
| 7959934 | Method for rapid generation of mature dendritic cells Novel methods of rapidly generating dendrtic cells are disclosed herein. The methods include contacting a dendritic cell precursor with a D ODN to generate a mature dendritic cell. In one specific, non-limiting example, the method includes contacting the dendritic c... | 06/14/2011 |
| 7956043 | 5′ CpG nucleic acids and methods of use The invention relates to a class of CpG immunostimulatory oligonucleotides containing a 5′TCG motif or a CG at or near the 5′ end that are useful for stimulating an immune response. ... | 06/07/2011 |
| 7951386 | genes and vaccines This invention provides the sequence of 5,299 nucleotides from the E. canis genome. There are four proteins, ProA, ProB, MmpA, and a cytochrome oxidase homolog, as well as a partial lipoprotein signal peptidase homolog at the carboxy terminus, coded for in th... | 05/31/2011 |
| 7927612 | Combinations and methods for treating neoplasms Methods for treating neoplasms, tumors and cancers, using one or more haptens and coagulation agents or treatments, alone or in combination with other anti-neoplastic agents or treatments, are provided. Also provided are combinations, and kits containing the combina... | 04/19/2011 |
| 7919477 | Multiple CpG oligodeoxynucleotides and their use to induce an immune response Compositions including multiple oligodeoxynucleotides with a CpG motif are disclosed herein. The compositions can include either D or K type oligodeoxynucleotides. These compositions are of use in inducing an immune response in a large percentage of the individuals ... | 04/05/2011 |
| 7914800 | LTBas vaccine adjuvant The present invention relates to a vaccine adjuvant for enhancing immune response of an individual to a vaccine, which comprises an immune-enhancing effective amount of an LTB4 agent in association with a pharmaceutically effective vaccine carrier. ... | 03/29/2011 |
| 7914801 | Metabolizable oil emulsion adjuvants and vaccines for enhancing immuno-properties of antibodies and their subpopulations Water-in-oil priming emulsion vaccines increase the titers and/or avidity indexes of antibodies following a second dose of a commercial or experimental vaccine resulting in increased protection for disease in animal. ... | 03/29/2011 |
| 7901694 | Method and apparatus for determining anticoagulant therapy factors Methods and apparatus are disclosed for determining a new anticoagulant therapy factors for monitoring oral anticoagulant therapy to help prevent excessive bleeding or deleterious blood clots that might otherwise occur before, during or after surgery. New anticoagul... | 03/08/2011 |
| 7892569 | Methods of altering an immune response induced by CpG oligodeoxynucleotides It is disclosed herein that agents that affect the activity and/or expression of CXCL16 can be used to alter the uptake of D-type CpG oligodeoxynucleotides (D ODNs). Methods of inducing an immune response are disclosed that include administering agents that increase... | 02/22/2011 |
| 7871630 | Therapeutic modulation of the tumor inflammatory response The invention relates to compositions, kits, and methods for alleviating cancer (i.e., a tumor) in a human patient. The therapeutic modality effected by the invention involves inducing a type 1 inflammatory response in the tumor tissue, whereby the tumor tissue is d... | 01/18/2011 |
| 7871631 | Methods of inhibiting the lowering of antihuman TNF-α antibody The present invention provides an antihuman TNF-α antibody activity lowering inhibitor comprising a protein source(s) and/or carbohydrate source(s), in the treatment of inflammatory bowel syndrome with repeated administration of anti-TNF-α antibody; and a kit prep... | 01/18/2011 |
| 7850981 | Immuno-adjuvant PDT treatment of metastatic tumors Immuno-adjuvant photodynamic therapy to treat and prevent metastatic cancer is effected using photosensitizers in combination with immuno-adjuvants to destroy metastatic tumor cells. ... | 12/14/2010 |
| 7838017 | Polyinosinic acid-polycytidylic acid-based adjuvant The present invention provides a polynucleotide adjuvant composition and methods of use in eliciting an immune response. The present invention also provides an immunogenic composition comprising the polynucleotide adjuvant composition together with an antigen (e.g.,... | 11/23/2010 |
| 7838018 | Adjuvant combinations for immunization composition and vaccines An adjuvant combination and a kit useful for immunization is provided. The kit contains an antigenic substance and an adjuvant combination of dimethyl dioctadecyl ammonium bromide (DDA-Br or DDA-Cl) with a monophosphoryl lipid. ... | 11/23/2010 |
| 7833538 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications. The invention provides methods for enhancing the immune response caused by immunostimulatory oligonucleotide compou... | 11/16/2010 |
| 7824696 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications. The invention provides methods for enhancing the immune response caused by immunostimulatory oligonucleotide compou... | 11/02/2010 |
